Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Frasca

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Thyroid : Official Journal of the American Thyroid Association|May 3, 2014
The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcomeMarco Russo, Pasqualino Malandrino, Maria Luisa Nicolosi, et al.
Endocrine-Related Cancer|December 3, 2005
The p53-homologue p63 may promote thyroid cancer progressionRoberta Malaguarnera, Angelo Mandarino, Emanuela Mazzon, et al.
The Journal of Pathology|February 10, 2009
Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomasLuca Lavra, Alessandra Ulivieri, Cinzia Rinaldo, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2013
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathwayFrancesco Frasca, Veronica Vella, Maria Luisa Nicolosi, et al.
Nutrients|January 25, 2025
Effects of Dietary Habits on Markers of Oxidative Stress in Subjects with Hashimoto's Thyroiditis: Comparison Between the Mediterranean Diet and a Gluten-Free DietMartina Laganà, Tommaso Piticchio, Angela Alibrandi, et al.
Cancers|July 29, 2025
Therapeutic Efficacy of a Very Low/Low Dose of Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer: A Real-World Series from a Single CenterVittorio Oteri, Fiorenza Gianì, Giulia Sapuppo, et al.
International Journal of Cancer|June 8, 2011
Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cellsRosa Linda Messina, Mariangela Sanfilippo, Veronica Vella, et al.
Cancers|October 29, 2020
Thyroid Cancer and Circadian Clock DisruptionRoberta Malaguarnera, Caterina Ledda, Agnese Filippello, et al.
Cancer Research|March 17, 2006
HMGA1 inhibits the function of p53 family members in thyroid cancer cellsFrancesco Frasca, Alessandra Rustighi, Roberta Malaguarnera, et al.
Endocrine|June 23, 2026
Diabetic gastroparesis: pathophysiology and impact on insulin timing choicesFrancesco Galeano, Andrea Tumminia, Vittorio Oteri, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Thyroid : Official Journal of the American Thyroid Association|May 3, 2014
The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcomeMarco Russo, Pasqualino Malandrino, Maria Luisa Nicolosi, et al.
Endocrine-Related Cancer|December 3, 2005
The p53-homologue p63 may promote thyroid cancer progressionRoberta Malaguarnera, Angelo Mandarino, Emanuela Mazzon, et al.
The Journal of Pathology|February 10, 2009
Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomasLuca Lavra, Alessandra Ulivieri, Cinzia Rinaldo, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2013
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathwayFrancesco Frasca, Veronica Vella, Maria Luisa Nicolosi, et al.
Nutrients|January 25, 2025
Effects of Dietary Habits on Markers of Oxidative Stress in Subjects with Hashimoto's Thyroiditis: Comparison Between the Mediterranean Diet and a Gluten-Free DietMartina Laganà, Tommaso Piticchio, Angela Alibrandi, et al.
Cancers|July 29, 2025
Therapeutic Efficacy of a Very Low/Low Dose of Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer: A Real-World Series from a Single CenterVittorio Oteri, Fiorenza Gianì, Giulia Sapuppo, et al.
International Journal of Cancer|June 8, 2011
Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cellsRosa Linda Messina, Mariangela Sanfilippo, Veronica Vella, et al.
Cancers|October 29, 2020
Thyroid Cancer and Circadian Clock DisruptionRoberta Malaguarnera, Caterina Ledda, Agnese Filippello, et al.
Cancer Research|March 17, 2006
HMGA1 inhibits the function of p53 family members in thyroid cancer cellsFrancesco Frasca, Alessandra Rustighi, Roberta Malaguarnera, et al.
Endocrine|June 23, 2026
Diabetic gastroparesis: pathophysiology and impact on insulin timing choicesFrancesco Galeano, Andrea Tumminia, Vittorio Oteri, et al.
Pageof 10